天元律师事务所、通商律师事务所近日分别以发行人中国律师和承销商中国律师身份，共同相继参与了医院运营企业海吉亚医疗和制药公司海普瑞在香港的成功上市。
在海吉亚项目中，天元香港联营所纪晓东律师行、美迈斯律师事务所同时担任发行人律师，高伟绅律师事务所则代表承销商参与交易；
在海普瑞项目中，达维律师事务所、霍金路伟律师事务所同时担任发行人律师，苏利文·克伦威尔律师事务所则作为承销商香港及美国法律师参与交易。
海吉亚医疗此次上市募资金额约为22.2亿港元。2009年创立于上海，海吉亚医疗的主营业务为连锁肿瘤治疗及脑科医疗机构的投资、建设及运营管理，目前为国内9省的15家医院的放疗中心提供服务。
海普瑞此次上市募资金额约为38亿港元，是今年生物科技领域迄今规模最大的港股IPO。1998年创立于深圳，海普瑞是目前中国最大、全球第三大依诺肝素钠制剂生产及销售商。其产品获得了美国FDA和欧盟CEP双认证，2019年在欧洲市场占有率高达17.8%。海普瑞2010年于深交所上市。
摩根士丹利、海通国际担任海吉亚项目的联席保荐人。
高盛、摩根士丹利担任海普瑞项目的联席保荐人。
衡力斯律师事务所同时参与了海吉亚项目。
海吉亚项目中，天元牵头律师为合伙人李竟弘、傅思齐、徐萍，同时得到合伙人王何维、杨喻意、汪丹丹律师协助；高伟绅牵头律师为合伙人方刘、向天宁；衡力斯牵头律师为合伙人吴洛汶。
海普瑞项目中，达维牵头律师为合伙人何鲤、褚洋；苏利文牵头律师为合伙人黄梓筠、林靖扬。
Tian Yuan, C&F lead on two medicine and healthcare IPOs in HK
Tian Yuan Law firm and Commerce & Finance Law Offices have led on two new health sector initial public offerings of Hygeia Healthcare and Hepalink Pharma in Hong Kong. They’ve advised the issuers and joint sponsors respectively in both deals.
Tian Yuan's Hong Kong associate firm William Ji & Co., O'Melveny＆Myers, and Clifford Chance also advised in the Hygeia deal, and the Hepalink deal includes Davis Polk & Wardwell, Hogan Lovells, and Sullivan & Cromwell.
Hygeia Healthcare raised $282 million in the IPO. Founded in 2009 in Shanghai, it’s the largest oncology healthcare group in China with a nationwide footprint of oncology-focused hospitals and radiotherapy centers.
Meanwhile, Hepalink raised $490 million in the IPO. Founded in 1998, the Shenzhen-based company is the third largest manufacturer and supplier of enoxaparin finished doses globally. Its market share in Europe was 17.8 percent in 2019. Hepalink was listed in Shenzhen back in 2010.
Morgan Stanley was the sponsor in both deals, with Haitong International Securities and Goldman Sachs acting as the other joint sponsors for Hygeia and Hepalink, respectively.
Harneys was offshore legal counsel in the Hygeia project, the team was led by partner Raymond Ng.
Tian Yuan’s partners Nan Li, Charles Wang, Fu Siqi, Xu Ping, Yang Yuyi and Wang Dandan, and Clifford Chance’s partners Fang Liu, Xiang Tianning have participated in the Hygeia deal;
Davis Polk’s partners He Li, Chu Yang, and Sullivan's partners Gwen Wong, Lin Ching-Yang led the Hepalink deal.
To contact the editorial team, please email ALBEditor@thomsonreuters.com.
